Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EnkaStim + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EnkaStim + Keytruda is a combination immunotherapy regimen being developed by Alphageneron for the treatment of metastatic Stage IV non-small cell lung cancer (NSCLC). The combination consists of EnkaStim, an autologous cell therapy comprising non-expanded natural killer (NK) cells targeted against membrane-bound Heat Shock Protein 70 (mHsp70), and Keytruda (pembrolizumab), a programmed cell death protein 1 (PD-1) blocking monoclonal antibody. mHsp70 is a tumor-specific antigen frequently expressed on the surface of various cancer cells, including NSCLC, but absent on normal tissues. By combining mHsp70-targeted NK cell cytotoxicity with the checkpoint inhibition provided by pembrolizumab, the therapy aims to leverage the direct cytotoxic activity of targeted NK cells while simultaneously reversing T-cell exhaustion to enhance the overall anti-tumor immune response. The program is currently in Phase 1 clinical development.
- Other names
- pembrolizumabautologous non-expanded targeted NK cells
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)HSPA1A (HSP70-1A)
Beyond the preview
Go deeper on EnkaStim + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EnkaStim + pembrolizumab.